


Supplemental Figure S1. Study Design

*Patients who completed the 16 weeks of double-blind treatment (Part A) were eligible for participation in an optional blinded long-term 36-week extension trial with active treatment (Part B).

ACR, American College of Rheumatology; QD, once daily.